Channel Therapeutics Company CHRO shares surged on Friday following the announcement of a reverse inventory cut up designed to help its upcoming company transformation and meet change itemizing necessities.
The clinical-stage biotech firm, targeted on creating non-opioid therapies for ache, revealed a 10-for-1 reverse inventory cut up of its widespread shares.
The transfer goals to spice up the per-share buying and selling worth and align with NYSE American itemizing requirements forward of a proposed merger with LNHC, Inc. and an related $50 million capital infusion led by Murchinson.
Additionally Learn: Healthcare AI Attracts Main Funding, Bucking Market Uncertainty
The reverse inventory cut up will change into efficient on July 1, 2025, earlier than the market opens. Buying and selling of the adjusted shares is about to start the next day, July 2, below the brand new identify Pelthos Therapeutics Inc.
Whereas the corporate’s ticker image will initially stay “CHRO,” it should change to “PTHS” upon the closing of the merger.
Because of the cut up, shareholders will obtain one new share for each 10 presently held, lowering excellent shares from about 6.5 million to roughly 648,500. Importantly, possession percentages for shareholders won’t be affected, and fractional shares shall be rounded up.
Stockholders with book-entry holdings or these utilizing brokers don’t have to take any motion.
The corporate’s switch agent, Nevada Company and Switch Firm (NATCO), will present particulars in regards to the modifications in share possession following the cut up.
Value Motion: CHRO shares are buying and selling increased by 2.56% to $1.200 eventually verify Friday.
Picture by way of Shutterstock
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
